{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-099424","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.867542+00:00","generated_at":"2026-05-15T16:44:50.182816+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prelude Therapeutics FY2025 net loss narrows to $99.5M; cash $106.4M; IND cleared for PRT12396","bullets":["Net loss of $99.5M ($1.29/share) improved from $127.2M ($1.68/share) in 2024.","Cash, equivalents and marketable securities $106.4M as of Dec 31, 2025; runway into Q2 2027.","FDA cleared IND for PRT12396 (mutant-selective JAK2V617F inhibitor); Phase 1 start expected Q2 2026.","KAT6A degrader PRT13722 IND filing planned mid-2026; Phase 1 initiation in H2 2026.","Exclusive option agreement with Incyte for JAK2 program (Nov 2025); DAC collaboration with AbCellera expanded."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-099424","json":"https://secwatch.observer/filing/0001193125-26-099424.json","markdown":"https://secwatch.observer/filing/0001193125-26-099424.md","text":"https://secwatch.observer/filing/0001193125-26-099424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/0001193125-26-099424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/prld-20260310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:44:50.182816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bf6eeeffea54dfbda73f87890489a038113ad97","claim":"Prelude Therapeutics Inc reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the full year ended December 31, 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/0001193125-26-099424-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}